Shares of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR - Get Free Report) have been given a consensus

Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tarsus Pharmaceuticals (NASDAQ: TARS - G

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR - Get Free Report) has been given a consensus recommendat

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwrig

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's reg

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.34) per share which beat the analyst co

$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses

$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTO

New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-uni

New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-univer

Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic

Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncolo

24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and f

$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $

$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citiu

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distr

CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius P

Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after the company announced a register

Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct

CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius P

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin

Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get

Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinica

(Editor’s note: The future prices of benchmark tracking ETFs and headline were updated in the story.